Ding Yunbu, Wang Chaofan, Bi Lingbo, Du Yimei, Lu Changpei, Zhao Min, Fan Weixin
Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China,
Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Dermatology. 2024;240(5-6):833-843. doi: 10.1159/000541395. Epub 2024 Sep 13.
Androgenetic alopecia (AGA) is a common skin disease characterized by gradually miniaturized hair follicles, which manifests as progressive hair thinning and produces a bald appearance. Currently, finasteride is approved by the Food and Drug Administration (FDA) for the treatment of AGA, but its efficacy remains poor in some patients.
Compared to finasteride, oral dutasteride has better efficacy and similar tolerability, and most adverse events are mild and reversible, making it an effective option for AGA, but its sexual adverse events and potential psychiatric risks still need to be concerned. Mesotherapy with dutasteride and microneedling combined with dutasteride solution can reduce adverse events caused by oral medication and exhibit certain efficacy, but standardized treatment protocols and large-scale clinical trials are still needed in the future. Liposomes or nanoparticles of dutasteride are under development and may become an efficient topical formulation.
We have summarized the efficacy and AEs of dutasteride in treating AGA under different administration methods and the promise of novel topical drug carriers.
雄激素性脱发（AGA）是一种常见的皮肤病，其特征为毛囊逐渐变小，表现为头发渐进性变细并出现秃发外观。目前，非那雄胺已获美国食品药品监督管理局（FDA）批准用于治疗AGA，但在部分患者中其疗效仍欠佳。
与非那雄胺相比，口服度他雄胺疗效更佳且耐受性相似，多数不良事件轻微且可逆，使其成为AGA的有效治疗选择，但其性方面的不良事件及潜在精神风险仍需关注。度他雄胺的中胚层疗法以及微针联合度他雄胺溶液可减少口服药物引起的不良事件并展现出一定疗效，但未来仍需要标准化治疗方案及大规模临床试验。度他雄胺的脂质体或纳米颗粒正在研发中，可能会成为一种高效的局部用药剂型。
我们总结了度他雄胺在不同给药方式下治疗AGA的疗效及不良事件，以及新型局部用药载体的前景。
